Ge Long Hui A P P·2025-10-11 07:32Core Viewpoint - Mindray Medical's mid-year performance meets expectations, with a projected turnaround in Q3 2025 due to improved domestic and overseas revenue growth [1] Group 1: Financial Performance - The decline in performance during the first half of the year was primarily due to domestic business challenges [1] - Q3 2025 is expected to show improved domestic revenue growth and enhanced overseas revenue growth, leading to a return to positive overall revenue growth [1] - Q4 is anticipated to continue the growth trend due to a low base effect [1] Group 2: Future Outlook - The company is expected to return to a stable growth trajectory next year [1] - In the medium to long term, the company emphasizes research and development innovation and internationalization, supported by an efficient R&D system and excellent channel management capabilities [1] - Strategic acquisitions are likely to further expand the company's market presence, with ongoing internationalization efforts positioning it to become one of the top 10 global medical device companies [1] Group 3: Internationalization and Supply Chain - The improvement of the IVD overseas supply chain is expected to accelerate the company's internationalization efforts [1]